Equivocal results of HER2 fluorescent in situ hybridization (FISH) assessment in breast cancer: Diagnostic limitations and therapeutical implications. This is an ASCO Meeting Abstract from the 2012 ...
CONCLUSION: The majority of patients with HER-2/neu–overexpressing cancers can develop immunity to both HER-2/neu peptides and protein. In addition, the generation of protein-specific immunity, after ...
Julie Fisher, MD: Hello, and welcome to Cure Expert Connections on HER2-positive breast cancer. I'm Dr Julie Fisher and I'm a medical breast oncologist at the Levine Cancer Institute in Charlotte, ...
Please provide your email address to receive an email when new articles are posted on . Tiersten: Historically HER2-positive breast cancers were considered to have a poor prognosis compared with other ...
Breast Tumor Section showing nonamplified HER-2/neu (<4 signals/nucleus). Cells are stained with DAPI. Probe is detected with flurorescein. There is perhaps nothing more disturbing to a woman than a ...
ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, ...
Poherdy is the first FDA-approved interchangeable biosimilar to Perjeta for HER2-positive breast cancer, potentially expanding access and reducing costs. Approved for use in combination with ...
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent ...
Shanghai Henlius Biotech and Organon have obtained permission from the Food and Drug Administration for Poherdy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback